Transfering to registration page. This presentation misleadingly implies that safety has been established in a larger number of patients than has been demonstrated by substantial evidence. The total number of prescriptions derived from IMS data does not support claims of safety or efficacy for Famvir. In addition, you present bar graphs of the median number of outbreaks in one year for Famvir and placebo as 1 vs. 5 outbreaks, respectively. These claims and presentation misrepresent trial results, implying that Famvir is more effective than demonstrated by substantial evidence.
Valacyclovir hydrochloride is converted to acyclovir.
This presentation is misleading because it implies clinical significance and suggests that Famvir is superior to valacyclovir hydrochloride or acyclovir because of its longer half-life when such has not been demonstrated by substantial evidence. SB should also include a list of all similarly violative materials being discontinued, as well as the date of discontinuation. Fishers Lane, Rockville, MD 20857.